For more information regarding these studies, contact Cancer Research and Registry at (601) 984‐1095.
SWOG S0919: A phase II study of idarubicin and ara-c in combination with prevastatin for relapsed acute myelogenous leukemia
The purpose of this study is to find out what effects, good and/or bad, the combination of regular chemotherapy plus pravastatin has on the patient and their disease. The chemotherapy in this study is made up of two drugs which are commonly used to treat relapsed acute myelogenous leukemia - idarubicin and AraC. Pravastatin is a drug that is usually used to treat high cholesterol. We would like to see whether adding pravastatin to the chemotherapy will have an effect the patient and the disease. Since pravastatin is not normally used to treat leukemia, the way we are using it in this study is experimental.
Principal Investigator: Stephanie Elkins, MD
E2906: Phase III Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin and Cytarabine Induction and Intermediate Dose Cytarabine Post Remission Therapy, followed by Decitabine Maintenance vs. Observation in Newly Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥ 60 years)
This study is being done to determine which treatment is better: standard induction chemotherapy, (Daunorubicin and Cytarabine), or Clofarabine alone. Clofarabine is not approved by the FDA for use in treating AML and is considered to be experimental in this research study. Older participants do not tolerate the standard therapy as well as younger participants and there is an indication that clofarabine may be better tolerated by older participants.
Principal Investigator: Stephanie Elkins, MD.
SGN33A-005: A Randomized, double-blind phase 3 study of vadastusimab talirine (SGN-CD33A_ versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)
The purpose of this study in AML patients is to test whether vadastuximab talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine improves remission rates and extends overall survival as compared to placebo combined with either azacitidine or decitabine.
S1318:A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL
The purpose of this study is to test any good and bad effects of adding the drug blinatumomab to different doses of standard combination of chemotherapy drugs. This will help to determine if these standard therapy drugs can be given at lower doses (when given with blinatumomab) in order to reduce overall side effects and be effective in treating ALL.) The addition of blinatumomab, an experimental drug, to usual treatment could help get rid of the leukemia cells and help keep them from coming back, but it could also cause side effects.
Researchers hope to learn if the addition of the study drug will keep the leukemia cells from coming back for a longer period of time than usual treatment alone. One of the other drugs being used, dasatinib, has been approved for other types of leukemia, but is experimental for this study.
2500 North State Street
Jackson, MS 39216
General Information: 601-984-1000
Patient Appointments: 888-815-2005